About 50% of patients with metastatic HER2-positive breast cancer will develop brain metastases. In recent years, the emergence of targeted therapy has significantly prolonged the survival of breast cancer patients. However, how to overcome the blood-brain barrier and improve the prognosis of breast cancer brain metastases remains a major challenge.
A recent study published in Nature sub-journal has confirmed that Enhertu is also effective in treating HER2-positive breast cancer patients with brain and/or meningeal metastases. Enhertu has excellent efficacy in the brain, with brain tumors shrinking or disappearing significantly in more than 60% of patients!
This study included 15 patients with HER2-positive breast cancer brain metastases, including newly diagnosed and previously untreated patients, patients whose disease progressed after previous local treatment, and patients with breast cancer brain metastases who had previously received trastuzumab and pertuzumab but did not respond well to local treatment.
The study results showed that 13.3% of breast cancer patients with brain metastases achieved complete intracranial remission, 60% achieved partial intracranial remission, and 20% had stable disease status; the best overall intracranial remission rate was 73.3%.
Enhertu has previously been approved by the FDA for use in patients with unresectable or metastatic HER2-positive breast cancer.
